Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Prostate. 2014 Jul 7;74(12):1209–1221. doi: 10.1002/pros.22837

Fig. 6.

Fig. 6

HNK treatment alters mTOR pathway in prostate cancer cells. Immunoblotting for mTOR signaling-related proteins using whole lysates from PC-3 and LNCaP cells treated with DMSO or various doses of HNK. Numbers on top of bands are fold change of level relative to corresponding DMSO-treated control.